Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Catalent, Inc.CTLT · Entity 16279 | EVP & Chief Financial Officer | August 24, 2017 | August 28, 2017 |
| Certara, Inc.CERT · Entity 787 | Director | May 14, 2026 | May 15, 2026 |
| MULTI COLOR CorpLABL · Entity 156212 | Director | October 03, 2016 | October 05, 2016 |
| Organon & Co.OGN · Entity 4115 | Chief Financial Officer | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Catalent, Inc.
Report date August 24, 2017 · Filed August 28, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 103,703 |
Last balance in matching sequence
After 2017-08-24 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-08-24 · Grant · Acquired 16,191 · Balance 111,948 F1: Received upon the achievement of the fiscal 2015-17 performance-based vesting criteria set forth in certain performance share units held by the reporting person. F2: Includes restricted stock units. Row 2 · 2017-08-24 · Tax withholding · Disposed 8,245 · Balance 103,703 F2: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Received upon the achievement of the fiscal 2015-17 performance-based vesting criteria set forth in certain performance share units held by the reporting person.
F2: Includes restricted stock units.
Certara, Inc.
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 213,316 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Exercise / conversion · Acquired 15,757 · Balance 213,316 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Exercise / conversion · Disposed 15,757 · Balance 0 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 33,222 |
Reported balance
After 2026-05-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-14 · Grant · Acquired 33,222 · Balance 33,222 F2: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.
F2: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.
MULTI COLOR Corp
Report date October 03, 2016 · Filed October 05, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,854 |
Reported balance
After 2016-10-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-10-03 · Grant · Acquired 994 · Balance 1,854 F1: Restricted stock granted pursuant to Multi-Color's 2012 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock granted pursuant to Multi-Color's 2012 Stock Incentive Plan.
Organon & Co.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,746 |
Ending reported balance
After 2026-03-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-31 · Exercise / conversion · Acquired 12,047 · Balance 202,707 Row 2 · 2026-03-31 · Tax withholding · Disposed 4,127 · Balance 198,580 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Row 3 · 2026-03-31 · Exercise / conversion · Acquired 21,546 · Balance 220,126 Row 4 · 2026-03-31 · Tax withholding · Disposed 7,380 · Balance 212,746 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 321,368 |
Reported balance
After 2026-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-31 · Grant · Acquired 321,368 · Balance 321,368 F2: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 83,472 |
Reported balance
After 2026-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-31 · Grant · Acquired 83,472 · Balance 83,472 F3: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-31 · Exercise / conversion · Disposed 12,047 · Balance 0 F4: Each RSU represents a contingent right to receive one share of Organon common stock. F5: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 43,094 |
Reported balance
After 2026-03-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-03-31 · Exercise / conversion · Disposed 21,546 · Balance 43,094 F4: Each RSU represents a contingent right to receive one share of Organon common stock. F6: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F3: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F4: Each RSU represents a contingent right to receive one share of Organon common stock.
F5: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
F6: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allergan plc
Report date May 08, 2020 · Filed May 12, 2020
Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-08 · Disposition to issuer · Disposed 12,039 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-05-08 · Disposition to issuer · Disposed 27,618 · Balance 0 F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-08 · Disposition to issuer · Disposed 28,021 · Balance 0 F3: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
F3: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2018 Filed Feb 22, 2018 21:25 UTC | Allergan plc AGN · Entity 149298 | GrantPerformance-Based Restricted Stock Unit · Derivative | 28,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002591 · edgar.xml · derivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,021 Underlying: Ordinary Shares · 28,021 shares Expires not disclosed F5 · derivative.exercise_price: Represents performance-based restricted share units ("PSUs") which will vest as to 50% of the total grant on each of December 31, 2020 and December 31, 2021, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of ordinary shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F5 · shares: Represents performance-based restricted share units ("PSUs") which will vest as to 50% of the total grant on each of December 31, 2020 and December 31, 2021, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of ordinary shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F5 · derivative.exercise_date: Represents performance-based restricted share units ("PSUs") which will vest as to 50% of the total grant on each of December 31, 2020 and December 31, 2021, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of ordinary shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F5 · derivative.expiration_date: Represents performance-based restricted share units ("PSUs") which will vest as to 50% of the total grant on each of December 31, 2020 and December 31, 2021, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of ordinary shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:25 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 9,340 | $160.59 | $1,499,910.60 |
DisclosureSEC source: 0001179110-18-002591 · edgar.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,416 F3 · shares: The reported securities are RSUs, each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 20% on each of February 20, 2019, February 20, 2020, February 20, 2021, February 20, 2022 and February 20, 2023. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:25 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 13,076 | $160.59 | $2,099,874.84 |
DisclosureSEC source: 0001179110-18-002591 · edgar.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,076 F1 · shares: The reported securities are restricted share units ("RSUs"), each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 25% on each of February 20, 2019, February 20, 2020, February 20, 2021 and February 20, 2022. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 16:29 UTC | Catalent, Inc. CTLT · Entity 16279 | Tax withholdingCommon Stock | 8,245 | $35.21 | $290,306.45 |
DisclosureSEC source: 0001596783-17-000142 · wf-form4_150393776858471.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,703 F2 · balance_after: Includes restricted stock units. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 16:29 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 16,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-17-000142 · wf-form4_150393776858471.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,948 F1 · kind: Received upon the achievement of the fiscal 2015-17 performance-based vesting criteria set forth in certain performance share units held by the reporting person. F2 · balance_after: Includes restricted stock units. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 22:35 UTC | Catalent, Inc. CTLT · Entity 16279 | Tax withholdingCommon Stock | 3,230 | $34.97 | $112,953.10 |
DisclosureSEC source: 0001596783-17-000096 · wf-form4_150162693642560.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,757 F1 · balance_after: Includes restricted stock units. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:46 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantOptions to purchase Common Stock · Derivative | 27,378 | $0.00 Strike: $36.02 | $0.00 |
DisclosureSEC source: 0001596783-17-000049 · wf-form4_150110556678064.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,378 Underlying: Common Stock · 27,378 shares Expires 2027-07-24 F3 · shares: Received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. F4 · derivative.exercise_date: The options vest in four equal annual installments beginning on July 24, 2018. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:46 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 5,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-17-000049 · wf-form4_150110556678064.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,987 F1 · shares: Restricted stock units received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:36 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 2,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596783-17-000042 · wf-form4_149729974863965.xml · nonDerivative · entry 5 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,712 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017 in order to implement a plan of financial diversification. F4 · price: These shares were sold in multiple transactions at prices ranging from $37.28 to $37.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:36 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionCommon Stock · Derivative | 20,374 | $0.00 Strike: $14.86 | $0.00 |
DisclosureSEC source: 0001596783-17-000042 · wf-form4_149729974863965.xml · derivative · entry 7 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,374 shares Expires 2021-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017 in order to implement a plan of financial diversification. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:36 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionCommon Stock · Derivative | 54,277 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001596783-17-000042 · wf-form4_149729974863965.xml · derivative · entry 6 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,277 shares Expires 2019-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017 in order to implement a plan of financial diversification. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:36 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 24,989 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596783-17-000042 · wf-form4_149729974863965.xml · nonDerivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,471 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017 in order to implement a plan of financial diversification. F3 · price: These shares were sold in multiple transactions at prices ranging from $36.77 to $37.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:36 UTC | Catalent, Inc. CTLT · Entity 16279 | Tax withholdingCommon Stock | 46,903 | $37.01 | $1,735,814.37 |
DisclosureSEC source: 0001596783-17-000042 · wf-form4_149729974863965.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,460 F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:36 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionCommon Stock | 20,374 | $14.86 | $302,757.64 |
DisclosureSEC source: 0001596783-17-000042 · wf-form4_149729974863965.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017 in order to implement a plan of financial diversification. F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:36 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionCommon Stock | 54,277 | $10.71 | $581,306.67 |
DisclosureSEC source: 0001596783-17-000042 · wf-form4_149729974863965.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017 in order to implement a plan of financial diversification. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 14:52 UTC | MULTI COLOR Corp LABL · Entity 156212 | GrantCommon Stock | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-144811 · doc4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,854 F1 · security: Restricted stock granted pursuant to Multi-Color's 2012 Stock Incentive Plan. Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 23:07 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock · Derivative | 20,374 | $0.00 Strike: $14.86 | $0.00 |
DisclosureSEC source: 0001596783-16-000133 · wf-form4_147380804533796.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,374 Underlying: Common Stock · 20,374 shares Expires 2021-10-11 F2 · kind: Due to the satisfaction of a market-based vesting condition, on September 9, 2016, the reporting person was issued 20,374 vested and exercisable options to purchase shares of common stock of the Issuer. Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 23:07 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock · Derivative | 54,277 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001596783-16-000133 · wf-form4_147380804533796.xml · derivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,277 Underlying: Common Stock · 54,277 shares Expires 2019-10-23 F1 · kind: Due to the satisfaction of a market-based vesting condition, on September 9, 2016, the reporting person was issued 54,277 vested and exercisable options to purchase shares of common stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.